One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Malignant Solid Tumors
- Interventions
- Drug: JCXH-211 Intratumoral Injection Combined with Anti-PD-1 Antibody IV infusion
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Immorna Biotherapeutics, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT06781125
A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
Phase 2
Active, not recruiting
- Conditions
- Herpes Zoster (HZ)Infectious DiseasesShingles
- Interventions
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Immorna Biotherapeutics, Inc.
- Target Recruit Count
- 467
- Registration Number
- NCT06581575
- Locations
- ๐บ๐ธ
Noble Clinical Research, Tucson, Arizona, United States
๐บ๐ธLong Beach Research Institute, Long Beach, California, United States
๐บ๐ธDM Clinical Research - Chicago, Chicago, Illinois, United States
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
Phase 1
Active, not recruiting
- Conditions
- Infectious DiseaseRespiratory Syncytial Virus (RSV)
- Interventions
- Other: Placebo
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Immorna Biotherapeutics, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT06564194
- Locations
- ๐บ๐ธ
Health Awareness, Jupiter, Florida, United States
๐บ๐ธDelRicht - New Orleans, New Orleans, Louisiana, United States
๐บ๐ธSundance Clinical Research, Saint Louis, Missouri, United States
A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
Phase 1
Active, not recruiting
- Conditions
- Herpes Zoster (HZ)ShinglesInfectious Disease
- Interventions
- Biological: Active Control (Shingrix)
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Immorna Biotherapeutics, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT05871541
- Locations
- ๐บ๐ธ
CenExel RCA, Hollywood, Florida, United States
๐บ๐ธCenExel FCR, Tampa, Florida, United States
๐บ๐ธCenExel HRI, Berlin, New Jersey, United States
A Phase 1/2 Study to Assess the Safety and Immunogenicity of JCXH-221, an mRNA-based Broadly Protective COVID-19 Vaccine
Phase 1
Recruiting
- Conditions
- Infectious DiseaseCOVID-19
- Interventions
- Other: Placebo
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Immorna Biotherapeutics, Inc.
- Target Recruit Count
- 262
- Registration Number
- NCT05743335
- Locations
- ๐บ๐ธ
Velocity Clinical Research, Cedar Park, Texas, United States
Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
Phase 1
Recruiting
- Conditions
- Malignant Solid TumorCutaneous Tumor
- Interventions
- Drug: JCXH-211 Injection
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Immorna Biotherapeutics, Inc.
- Target Recruit Count
- 156
- Registration Number
- NCT05727839
- Locations
- ๐จ๐ณ
Sun Yat-sen University Cancer Center, Guangdong, Guangzhou, China
Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Malignant Solid TumorCutaneous Tumor
- Interventions
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Immorna Biotherapeutics, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT05539157
- Locations
- ๐บ๐ธ
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath